XDH and chronic kidney disease: On the other hand, a recent systematic review and meta-analysis of 11 randomized clinical trials, including 4,277 participants with CKD, suggested that UA-lowering therapy preserves GFR so that xanthine oxidoreductase inhibitors could improve renal outcomes50.